Daratumumab for Antiphospholipid Syndrome

(DARE-APS Trial)

Recruiting in Palo Alto (17 mi)

+7 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Recruiting

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Must be taking: Warfarin, LMWH

Must not be taking: Corticosteroids, DOACs, Biologics, others

Disqualifiers: Systemic autoimmune diseases, Active infection, others

No Placebo Group

Breakthrough Therapy

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial is testing if daratumumab, an IV medication, is safe for people with Anti-Phospholipid Syndrome (APS). APS patients are being studied because they may not respond well to usual treatments. Daratumumab works by helping the immune system target specific cells that might be causing issues.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications before participating. Specifically, you must not have used corticosteroids over 10 mg/day, direct oral anticoagulants, certain immunosuppressive drugs, or biologic agents within specified time frames before joining the study. If you are on warfarin or low molecular weight heparin due to a history of thrombosis, you may continue these medications.

What data supports the effectiveness of the drug Daratumumab for treating Antiphospholipid Syndrome?

Daratumumab has shown effectiveness in treating multiple myeloma, a type of blood cancer, by inducing strong and lasting responses in patients. It has also been used successfully in treating immune thrombocytopenia (a condition where the immune system attacks platelets) by targeting cells that produce harmful antibodies, suggesting potential benefits for other immune-related conditions. ^{1 2 3 4 5}

Is Daratumumab generally safe for humans?

The safety of biological therapies, like Daratumumab, has been studied in various conditions, primarily in rheumatic diseases. These studies often focus on the risk of severe adverse events (serious side effects) within a few months of treatment. While specific data on Daratumumab for Antiphospholipid Syndrome is not available, safety registers for similar treatments help monitor and report any safety concerns. ^{6 7 8 9 10}

How is the drug Daratumumab different from other treatments for antiphospholipid syndrome?

Daratumumab is unique because it is an immunotherapy drug that targets specific proteins on immune cells, unlike traditional treatments for antiphospholipid syndrome which primarily focus on anticoagulation to prevent blood clots. This approach may offer a novel way to address the underlying immune system dysfunction in this condition. ^{11 12 13 14 15}

Research Team

Doruk Erkan, M.D., M.P.H.

Principal Investigator

Hospital for Special Surgery, New York: Division of Rheumatology

Jason Knight, M.D., Ph.D.

Principal Investigator

University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology

Eligibility Criteria

This trial is for adults aged 18-65 with Anti-Phospholipid Syndrome (APS), who meet specific criteria including a history of certain types of thrombosis or pregnancy complications related to APS. Participants must have completed recommended vaccinations, be willing to use warfarin or LMWH for anticoagulation, and not have other autoimmune disorders like rheumatoid arthritis or systemic lupus erythematosus.

Inclusion Criteria

History of triple positive aPL within the prior 5 years and at least 12 weeks prior to enrollment

I am between 18 and 70 years old.

Willing and able to discontinue direct oral anticoagulants if applicable

Exclusion Criteria

Inability or unwillingness to give written informed consent

Inability or unwillingness to comply with study protocol

I have an ongoing infection.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Participants receive weekly intravenous administration of daratumumab for 8 doses to determine the highest safe dose

8 weeks

8 visits (in-person)

Expansion Phase

Four additional participants are treated at the highest safe dose weekly for 8 doses

8 weeks

8 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

48 weeks

6 visits (in-person) at weeks 9, 12, 18, 24, 36, and 48

Treatment Details

Interventions

• Daratumumab (Monoclonal Antibodies)

Trial Overview The study tests the safety of daratumumab at different doses (4 mg/kg, 8 mg/kg, and 16 mg/kg) in treating APS. Up to 22 participants will receive intravenous doses on a set schedule to identify any dose-limiting toxicities during this phase.

Participant Groups

Group I: 8 mg/kg Cohort Experimental Treatment 1 Intervention

This cohort will receive intravenous (IV) administration of 8 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48

Group II: 4 mg/kg Cohort Experimental Treatment 1 Intervention

This cohort will receive intravenous (IV) administration of 4 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48

Group III: 16 mg/kg Cohort Experimental Treatment 1 Intervention

This cohort will receive intravenous (IV) administration of 16 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48

Who Is Running the Clinical Trial?

National Institute of Allergy and Infectious Diseases (NIAID)

Lead Sponsor

Trials

3,361

Recruited

5,516,000+

Dr. Jeanne Marrazzo

National Institute of Allergy and Infectious Diseases (NIAID)

Chief Executive Officer since 2023

MD, MPH

Dr. H. Clifford Lane

National Institute of Allergy and Infectious Diseases (NIAID)

Chief Medical Officer

MD

PPD DEVELOPMENT, LP

Industry Sponsor

Trials

167

Recruited

38,000+

David Simmons

PPD DEVELOPMENT, LP

Chief Executive Officer since 2012

BSc in Applied Science from Georgia Institute of Technology

Martina Flammer

PPD DEVELOPMENT, LP

Chief Medical Officer since 2024

MD

Immune Tolerance Network (ITN)

Collaborator

Trials

68

Recruited

7,900+

Dr. Mark Anderson

Immune Tolerance Network (ITN)

Chief Executive Officer since 2000

MD, PhD from University of California, San Francisco

Dr. Dawn Smilek

Immune Tolerance Network (ITN)

Chief Medical Officer since 2021

MD, PhD

PPD

Industry Sponsor

Trials

162

Recruited

36,600+

Dr. Austin Smith

PPD

Chief Medical Officer since 2020

Doctor of Medicine from the Royal College of Surgeons in Ireland

David Simmons

PPD

Chief Executive Officer since 2012

Bachelor’s degree in Applied Mathematics and Industrial Management from Carnegie Mellon University

Rho Federal Systems Division, Inc.

Industry Sponsor

Trials

44

Recruited

15,000+

Findings from Research

Daratumumab, an anti-CD38 monoclonal antibody, was used off-label to treat two adult patients with primary immune thrombocytopenia (ITP) after standard therapies failed, showing promising results in one patient with rapid and lasting improvement in platelet counts.

The treatment appears to effectively target long-lived plasma cells that produce antiplatelet autoantibodies, suggesting that daratumumab could be a valuable option for ITP and warrants further clinical evaluation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Daratumumab as a novel treatment option in refractory ITP. Vernava, I., Schmitt, CA.[2023]

Daratumumab, a monoclonal antibody targeting CD38, has been approved in the USA for treating multiple myeloma in patients who have undergone at least three prior therapies, demonstrating its role as a treatment option for difficult-to-treat cases.

In a phase II trial, daratumumab monotherapy showed an overall response rate of about 30% in patients with relapsed or refractory multiple myeloma, indicating its efficacy in this challenging patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Daratumumab: First Global Approval. McKeage, K.[2018]

Daratumumab, a monoclonal antibody for treating refractory multiple myeloma, can be detected in serum protein electrophoresis, appearing as an additional band in the slow gamma region.

It is crucial for diagnostic laboratories to recognize daratumumab in test results to avoid misinterpretation as a new monoclonal protein, ensuring accurate patient management.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Electrophoretic patterns post daratumumab. Sheldon, J., Wheeler, RD., Powles, R.[2018]

Intravenous daratumumab, when combined with bortezomib, thalidomide, and dexamethasone, significantly improves treatment outcomes for adults with newly diagnosed multiple myeloma, leading to higher rates of stringent complete response and prolonged progression-free survival, as shown in the phase III CASSIOPEIA trial.

The addition of daratumumab has a minimal impact on overall toxicity, with the most common serious side effects being blood-related issues, indicating it is a relatively safe option for patients undergoing treatment for multiple myeloma.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma. Lamb, YN.[2021]

The BIOBADASER III registry, initiated in December 2015, includes data from 2,664 patients with rheumatic diseases treated with biological or synthetic drugs, focusing on tracking adverse events and treatment effectiveness.

In the first year, the most common adverse events reported were infections and infestations, highlighting the need for ongoing monitoring of safety in patients undergoing long-term treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Objectives and methodology of BIOBADASER phase iii. Sanchez-Piedra, C., Hernández Miguel, MV., Manero, J., et al.[2021]

In a 6-month trial involving 107 patients with various rheumatic diseases, treatment with biological agents like rituximab and infliximab led to significant improvements, with 57.9% achieving complete remission and 39.3% achieving partial remission.

The incidence of severe adverse events (AEs) was relatively low, with only 5.6% of patients experiencing serious AEs, including severe infusion reactions and systemic infections, indicating that while risks exist, the benefits of using biological agents in managing rheumatic diseases are notable.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases]. Moiseev, SV., Novikov, PI., Semenkova, EN., et al.[2015]

The establishment of European biologics registers for rheumatic diseases is crucial for improving drug safety assessments, and a set of seven key considerations has been identified to guide the creation of these registers.

To enhance the quality and interpretability of safety data, nine additional points for analysis and reporting have been proposed, emphasizing the importance of thoughtful design and harmonization in future studies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Dixon, WG., Carmona, L., Finckh, A., et al.[2022]

This erratum corrects information from a previous study that evaluated the risk of major adverse cardiovascular events in psoriasis patients undergoing biologic therapy.

The original study aimed to assess the safety of biologic treatments in terms of cardiovascular health, but specific details on the number of subjects or findings are not provided in the erratum.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Evaluation of Risk of Major Adverse Cardiovascular Events with Biologic Therapy in Patients with Psoriasis (Errata). Bissonnette, R., Langholff, W.[2021]

BIOBADASER, the Safety Register of the Spanish Society of Rheumatology, has successfully served as a template for creating other safety registers, such as BIOBADAMERICA and BIOBADADERM, highlighting its influence in standardizing data collection in rheumatology and beyond.

While template registers like BIOBADASER improve data collection and communication of safety concerns, they also face challenges in merging rare data and making comparisons across different registers due to their varied structures.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries. Carmona, L., de la Vega, M., Ranza, R., et al.[2017]

Patients with triple-positive antiphospholipid syndrome (APS) are at the highest risk for thrombotic events, even with anticoagulation, leading to recommendations against using direct-acting oral anticoagulants (DOACs) for secondary prevention in all APS patients.

The review highlights a lack of evidence for the safety and efficacy of DOACs in patients with single- or dual-positive APS, suggesting that the current guidelines may be overly cautious and warrant further investigation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome? Arachchillage, DRJ., Laffan, M.[2020]

Direct-acting oral anticoagulants (DOACs) like rivaroxaban and apixaban are significantly less effective than vitamin K antagonists (VKAs) in preventing thrombosis recurrence in patients with antiphospholipid syndrome (APS), especially those with prior arterial thrombosis or multiple antiphospholipid antibodies.

The risk of severe bleeding as a side effect is similar for both DOAC and VKA treatments, suggesting that DOACs may not be a safe or effective option for managing thrombotic APS.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Direct-acting oral anticoagulants in antiphospholipid syndrome: A systematic review]. Girón-Ortega, JA., Girón-González, JA.[2023]

Direct-acting oral anticoagulants (DOACs), such as rivaroxaban, are emerging as first-line therapy for antiphospholipid syndrome (APS) due to their effectiveness in preventing thrombosis without the need for regular monitoring, unlike warfarin.

Clinical studies indicate that DOACs are non-inferior to warfarin in various anticoagulation scenarios, making them a promising option for managing APS and its associated thrombotic risks.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome. Arora, S., Nair, S., Prabhu, R., et al.[2021]

In a study of 22 patients with antiphospholipid syndrome (APS), both low-dose and standard-dose rituximab (RTX) were found to be effective, with 42.1% of patients achieving complete remission after 6 months of treatment.

The study indicated that low-dose RTX (<1000mg) had similar efficacy to standard-dose RTX (≥1000mg) in reducing anticardiolipin antibody levels and improving patient outcomes, suggesting that lower doses may be a safe and effective treatment option.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Low dose versus standard dose rituximab for the treatment of antiphospholipid syndrome: A pilot study from a tertiary medical center. Gan, Y., Zhong, X., Zhao, Y., et al.[2022]

Antiphospholipid syndrome (APS) is a serious autoimmune disorder that leads to recurrent blood clots and pregnancy complications, and traditional anticoagulation treatments often fail to prevent these issues in many patients.

While direct oral anticoagulants are a promising alternative to standard treatments, they may not be effective for high-risk APS patients, prompting research into other therapies like immunomodulators and novel agents to improve patient outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An update on the management of antiphospholipid syndrome. Rodziewicz, M., D'Cruz, DP.[2020]

References

1. New Zealand pubmed.ncbi.nlm.nih.gov

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma. [2018]

2. United States pubmed.ncbi.nlm.nih.gov

Daratumumab as a novel treatment option in refractory ITP. [2023]

3. New Zealand pubmed.ncbi.nlm.nih.gov

Daratumumab: First Global Approval. [2018]

4. England pubmed.ncbi.nlm.nih.gov

Electrophoretic patterns post daratumumab. [2018]

5. New Zealand pubmed.ncbi.nlm.nih.gov

Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma. [2021]

6. Spain pubmed.ncbi.nlm.nih.gov

Objectives and methodology of BIOBADASER phase iii. [2021]

7. Russia (Federation) pubmed.ncbi.nlm.nih.gov

[Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases]. [2015]

8. England pubmed.ncbi.nlm.nih.gov

EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. [2022]

9. United States pubmed.ncbi.nlm.nih.gov

Evaluation of Risk of Major Adverse Cardiovascular Events with Biologic Therapy in Patients with Psoriasis (Errata). [2021]

10. Italy pubmed.ncbi.nlm.nih.gov

BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries. [2017]

11. England pubmed.ncbi.nlm.nih.gov

What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome? [2020]

12. Spain pubmed.ncbi.nlm.nih.gov

[Direct-acting oral anticoagulants in antiphospholipid syndrome: A systematic review]. [2023]

13. United States pubmed.ncbi.nlm.nih.gov

Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome. [2021]

14. Switzerland pubmed.ncbi.nlm.nih.gov

Low dose versus standard dose rituximab for the treatment of antiphospholipid syndrome: A pilot study from a tertiary medical center. [2022]

15. England pubmed.ncbi.nlm.nih.gov

An update on the management of antiphospholipid syndrome. [2020]